Identification of Novel Binding Interactions in the Development of Potent, Selective 2-Naphthamidine Inhibitors of Urokinase. Synthesis, Structural Analysis, and SAR of N-Phenyl Amide 6-Substitution
- 12 December 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (2) , 303-324
- https://doi.org/10.1021/jm0300072
Abstract
The preparation and assessment of biological activity of 6-substituted 2-naphthamidine inhibitors of the serine protease urokinase plasminogen activator (uPA, or urokinase) is described. 2-Naphthamidine was chosen as a starting point based on synthetic considerations and on modeling of substituent vectors. Phenyl amides at the 6-position were found to improve binding; replacement of the amide with other two-atom linkers proved ineffective. The phenyl group itself is situated near the S1‘ subsite; substitutions off of the phenyl group accessed S1‘ and other distant binding regions. Three new points of interaction were defined and explored through ring substitution. A solvent-exposed salt bridge with the Asp60A carboxylate was formed using a 4-alkylamino group, improving affinity to Ki = 40 nM. Inhibitors also accessed two hydrophobic regions. One interaction is characterized by a tight hydrophobic fit made with a small dimple largely defined by His57 and His99; a weaker, less specific interaction involves alkyl groups reaching into the broad prime-side protein binding region near Val41 and the Cys42-Cys58 disulfide, displacing water molecules and leading to small gains in activity. Many inhibitors accessed two of these three regions. Affinities range as low as Ki = 6 nM, and many compounds had Ki < 100 nM, while moderate to excellent selectivity was gained versus four of five members of a panel of relevant serine proteases. Also, some selectivity against trypsin was generated via the interaction with Asp60A. X-ray structures of many of these compounds were used to inform our inhibitor design and to increase our understanding of key interactions. In combination with our exploration of 8-substitution patterns, we have identified a number of novel binding interactions for uPA inhibitors.Keywords
This publication has 37 references indexed in Scilit:
- Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancersBiochemical Society Transactions, 2002
- The urokinase receptor. A cell surface, regulated chemokineAPMIS, 1999
- Urokinase Plasminogen Activator Colocalizes with CD25+ Cells in Atherosclerotic VesselsJournal of Vascular Research, 1998
- Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient miceOncogene, 1998
- Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formationNature Genetics, 1997
- Induction of Vascular SMC Proliferation by Urokinase Indicates a Novel Mechanism of Action in Vasoproliferative DisordersArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor modelBreast Cancer Research and Treatment, 1996
- Prevention of prostate‐cancer metastasis in vivo by a novel synthetic inhibitor of urokinase‐type plasminogen activator (uPA)International Journal of Cancer, 1995
- Augmented Urokinase Receptor Expression in AtheromaArteriosclerosis, Thrombosis, and Vascular Biology, 1995